Mayne Pharma | MYX - Interest Expense On Debt

Stock Price
4.57
Daily Change
0.07 1.44%
Monthly
-8.70%
Yearly
-4.50%
Q3 Forecast
5.25

Mayne Pharma reported AUD1.2M in Interest Expense on Debt for its fiscal semester ending in June of 2024.



Financials
Stock Price AUD
Assets AUD 1.14B
Cash and Equivalent AUD 110.07M
Cost of Sales AUD 43.74M
Current Assets AUD 460.59M
Current Liabilities AUD 313.94M
Debt AUD 38.82M
Dividend Yield 0
EBIT AUD -16.2M
EBITDA AUD -65.76M
Employees 900
EPS Earnings Per Share AUD -0.89
Equity Capital and Reserves AUD 454.19M
Gross Profit on Sales AUD 115.99M
Interest Expense on Debt AUD 1.2M
Loan Capital AUD 31.64M
Market Capitalization AUD 382.83M
Net Income AUD -103.68M
Operating Expenses AUD 103.54M
Operating Profit AUD -3.3M
Ordinary Share Capital AUD 1.22B
Pre-Tax Profit AUD -57.61M
Sales Revenues AUD 195.04M
Selling and Administration Expenses AUD 54.8M
Stock AUD 74.63M
Trade Creditors AUD 20.87M
Trade Debtors AUD 193.22M

Interest Expense On Debt Change Date
Ansell USD 5.6M 4.8M Jun/2024
Avita Medical AUD 1.35M 230K Jun/2024
Cochlear AUD 5.7M 800K Dec/2024
CSL USD 240M 18M Dec/2024
Healius AUD 32.8M 15.4M Dec/2024
Integral Diagnostics AUD 5.34M 6.08M Jun/2024
Medical Developments International AUD 21K 23K Jun/2024
Nanosonics AUD 313K 73K Jun/2024
Polynovo AUD 178K 131K Jun/2024
Ramsay Health Care AUD 305.7M 700K Dec/2024
ResMed USD 775K 886K Dec/2024
Sigma Healthcare AUD 7.97M 365K Jan/2024
Sonic Healthcare AUD 86.91M 43.94M Dec/2024
Telix Pharmaceuticals AUD 3.39M 2.92M Dec/2024